Neoplasms

All Conditions

Adenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

All Drugs and Chemicals

Gastrointestinal Agents

Immunomodulating Agents

Pancrelipase

Pancreatin

Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.

Investigators are allowed to chose the best option of standard treatment for patients.

Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.

Personalised treatment

Investigators are allowed to chose what they consider the best standard treatment option for their patients.

Treatment chosen per investigator´s judge

Manuel Hidalgo, PhD

This is a multicenter, open label, randomised phase II clinical trial for patients with metastatic adenocarcinoma of the pancreas. Patients randomised to the experimental arm will undergone tumoral biopsy before starting first line of treatment and will be administered personalised therapy as second or third line.

This is a multicenter, open label, randomised phase II clinical trial for patients with metastatic adenocarcinoma of the pancreas.

Patients with metastatic disease will be randomised to the experimental or control arms. Those in the experimental arm will undergone a tumoral biopsy in order to perform exome sequencing, bioinformatic report, and avatar mouse models for drug testing. This information will allow the expertise panel to elaborate a treatment recommendation as second or third lines of treatment. Patients in the control arm will receive treatment as per investigator´s judge. The main objective of the trial is to determine whether personalised treatments achieve improved 1-year overall survival.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation	NCT02795650	Adenocarcinoma	Personalised tr... Treatment chose...	18 Years -	Hospital Universitario de Fuenlabrada
Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation	NCT02795650	Adenocarcinoma	Personalised tr... Treatment chose...	18 Years -	Hospital Universitario de Fuenlabrada

Spots Global Cancer Trial Database for treatment chosen per investigator´s judge